Combinatorial Targeting of Immune Checkpoints and Epigenetic Regulators for Hepatocellular Carcinoma Therapy

Scientists outline current immune checkpoint inhibitors (ICI) treatments for HCC and how ICIs can be combined with distinct epigenetic inhibitors to increase the durability of ICIs and potentially treat “immune-cold” HCC.